.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
India has achieved a landmark milestone in managing rare genetic conditions through the establishment of a specialized repository. The newly inaugurated Lysosomal Storage Disorders Biobank in Gujarat offers significant hope for patients seeking affordable diagnostic pathways. Consequently, this facility at the FRIGE's Institute of Human Genetics consolidates two decades of rigorous clinical research. Furthermore, the repository currently manages biological samples from more than 530 patients across the country.
The facility serves as a critical infrastructure for identifying complex genetic mutations in a resource-limited setting. By integrating DNA data with detailed clinical profiles, researchers can now accelerate the development of indigenous medical solutions. Moreover, the biobank includes serum, plasma, and genomic DNA samples to support long-term healthcare outcomes. Although treatment costs for these conditions often exceed Rs 1 crore annually, this initiative aims to lower economic barriers. Therefore, clinicians can expect improved access to cost-effective diagnostic kits in the near future.
The institute recently developed a molecular probe-based sequencing asset to streamline the identification of rare metabolic conditions. This technological advancement allows for the comprehensive diagnosis of 19 different lysosomal storage disorders simultaneously. Additionally, the Gujarat State Biotechnology Mission provided essential funding to foster this genetic innovation. Because the biobank functions as a national resource, it strengthens India's self-reliance in advanced medical research. Ultimately, these efforts position Gujarat as a primary hub for global genetic advancements.
Q1: What types of biological samples does the new biobank store?
The biobank maintains a comprehensive repository including serum, plasma, whole blood genomic DNA samples, and urine precipitates from over 530 patients.
Q2: How does the biobank impact the cost of diagnosing rare disorders?
By utilizing indigenous molecular probe-based sequencing assets, the facility significantly reduces the cost of diagnosing multiple disorders compared to traditional methods.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Gujarat launches India's first national biobank for Lysosomal Storage Disorders to provide affordable diagnosis and genetic research for rare diseases....
6 months ago
A retrospective cohort study of 7,716 ICU patients from the MIMIC-IV database demonstrates that Gradient Boosting Decision Trees significantly outperform traditional SOFA scores in predicting in-hospital mortality among patients with sepsis and diabetes, with SHAP analysis providing clinical interpretability.
Today
A prenatal case highlights severe glutaric acidemia type II presenting as bilateral hyperechoic cystic kidneys at 18 weeks. Whole-exome sequencing revealed a novel homozygous ETFDH frameshift variant, demonstrating the power of rapid genetic testing in fetal renal anomalies.
Today
This article reviews the forensic and clinical complexities of acute myocarditis arising on left ventricular hypertrophy in children, highlighting early diagnostic red flags and multidisciplinary postmortem autopsy protocols.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Yesterday
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Yesterday
